Optical imaging developer VisEn Medical of Bedford, MA, has launched its new GastroSense 750 fluorescence agent for in vivo imaging of gastric motility and related drug effects.
GastroSense 750 is designed for real-time quantitative measurements of gastric motility in animal models, thereby enabling assessment of a variety of related diseases and drug effects in preclinical research and drug development.
Related Reading
VisEn rolls out VivoTag, March 12, 2010
VisEn buys rights to fluorescence agents, January 28, 2010
VisEn launches imaging agent, January 19, 2010
VisEn debuts new molecular imaging agents, November 20, 2009
VisEn debuts molecular agent, FMT systems, September 24, 2009
Copyright © 2010 AuntMinnie.com
![Axial images from unenhanced calcium score cardiac CT (left) and curved planar reformation images from CT angiography (right) show that higher long-term exposure to air pollution is associated with greater coronary artery calcium and more obstructive coronary artery disease (CAD). Top row: Images in a 68-year-old male patient with higher 10-year mean ambient air pollution exposure (7.9 μg/m3 for particulate matter measuring ≤2.5 μm in diameter [PM2.5] and 17.4 parts per billion [ppb] for NO2) with extensive CAD (coronary artery calcium score [CACS] >1,000 and obstructive CAD [≥70% diameter stenosis]). Bottom row: Images in a 57-year-old female patient with lower 10-year mean ambient air pollution exposure (6.3 μg/m3 for PM2.5 and 4.6 ppb for NO2) with no CAD (CACS = 0 and no obstructive stenosis).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/06/hanneman.r6SMLzkezo.png?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
